Trastuzumab biosimilar (BioIntegrator)

曲妥珠单抗生物类似药（BioIntegrator）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (BioIntegrator)

Drug Alias Name曲妥珠单抗生物仿制药（BioIntegrator）BI-Mab-03

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiointegrator Llc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeL01XC03